Prosecution Insights
Last updated: April 19, 2026

Elanco US Inc.

7 pending office actions

Portfolio Summary

7
Total Pending OAs
3
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18569414 CRYSTALLINE FORMS OF ISOXAZOLINE COMPOUND ENGLISH, CONNOR KENNEDY 1625 Non-Final OA Dec 12, 2023
18212953 ANTIMICROBIAL CLAY COMPOSITIONS AND METHODS OF USING JOHNSON, DANIELLE D 1617 Final Rejection Jun 22, 2023
18249869 JAK INHIBITORS HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION PALENIK, JEFFREY T 1615 Final Rejection Apr 20, 2023
17996557 LONG-ACTING ANTI-IL31 ANTIBODIES FOR VETERINARY USE ALLEN, MARIANNE P 1647 Non-Final OA Oct 19, 2022
17996549 IL4/IL13 RECEPTOR MOLECULES FOR VETERINARY USE KONOPELSKI SNAVEL, SARA ELIZABETH 1658 Non-Final OA Oct 19, 2022
17682822 ANTIVIRAL EFFECTS OF NARASIN IN SWINE FEED BORI, IBRAHIM D 1629 Final Rejection Feb 28, 2022
17524709 CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE PHAN, DOAN THI-THUC 1613 Non-Final OA Nov 11, 2021

Managing Elanco US Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month